, , , , , , , ,

I recently read an article about some big advances regarding Bioheart, Inc., a company focused on the discovery and development of autologous cell therapies for the treatment of cardiovascular diseases. Bioheart has begun establishing five Stem Cell Centers of Excellence in Latin America to provide its autologous adult stem cell (A-ASC) therapy procedures to patients suffering from congestive heart failure (CHF) and peripheral arterial disease (PAD).

The first center of Excellence is at the Regenerative Medicine Institute at Hospital Angeles Tijuana. I’ve talked quite extensively about Angeles Health International, which makes up the largest private hospital network in Mexico. Hospital Angeles is frequently recognized for its cutting edge medical technology and well trained physicians, and is a frequent medical travel destination for individuals coming from around the globe. 

The Regenerative Medicine Institute at Hospital Angeles has just finished the first phase of Stem Cell Clinic Accreditation with the International Cellular Medicine Society (ICMS.) These advances mark tremendous steps forward in the medical tourism industry, as well as the world of stem cell treatment.

Some patients have such severe heart failure that their only current option is a heart transplant, said Dr. Brian Bruckner, cardiac surgeon at the Methodist DeBakey Heart & Vascular Center in Houston. We hope that stem cells will stimulate angiogenesis, the growth of new blood vessels, restore mechanical function in diseased heart tissue, and return patients to a much better quality of life without a transplant.